Tag: options

NEW YORK, June 13, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announces that dosing has commenced at the prestigious Weill Cornell Medicine Multiple Sclerosis Center in New York City, in its ongoing Phase 2 clinical trial evaluating intranasal foralumab in patients with non-active Secondary Progressive Multiple Sclerosis (na-SPMS). This fifth site complements existing sites at Yale University, Johns Hopkins University, Brigham and Women's Hospital, and the University of Massachusetts.

SOUTH SAN FRANCISCO, Calif., June 13, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options to purchase an aggregate of 26,000 shares of the Company’s stock (the “Inducement Grant”) to newly hired employees on June 10, 2025 (the “Grant Date”), in connection with the commencement of employment.

MIAMI, June 13, 2025 (GLOBE NEWSWIRE) -- AYR Wellness Inc. (CSE: AYR.A, OTCQX: AYRWF) (“AYR” or the “Company”), a leading vertically integrated U.S. multi-state cannabis operator, announces that it has not completed the filing of its interim financial statements, management’s discussion and analysis, and related CEO and CFO certificates for the three-month period ended March 31, 2025 (collectively, the “Interim Filings”) by the previously anticipated date of June 13, 2025.‎

New clinical results show sustained CRi, deep bone marrow responses, and encouraging survival in FLT3-mutant AML patients, including those previously treated with gilteritinib

FORM 8.3

NEW YORK, June 12, 2025 (GLOBE NEWSWIRE) -- Luvme Hair, a trusted name in premium human hair wigs and clip-in hair extensions, is thrilled to announce its highly anticipated 2025 Mid-Year Sale. This exclusive event offers customers discounts of up to $110 on a wide selection of high-quality wigs. Known for their exceptional craftsmanship, comfort, and natural appearance, Luvme Hair wigs provide the perfect solution for anyone looking to enhance their style effortlessly.